Topic: inflammatory diseases
Scientists in Spain found a way to capitalize on a natural mechanism by which immune cells called neutrophils regulate their own activity in the body.
Alexis Borisy is leading a new kind of biotech company that will “reshape the industry” by introducing new medicines at “radically lower” prices.
Fresh off a $55.5 million round, IFM Therapeutics snagged a new chief scientific officer. Michael Cooke, Ph.D., joins from stem cell biotech Magenta.
Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.
IFM Therapeutics promoted its R&D chief Martin Seidel, Ph.D., to CEO and reeled in $55.5 million to fund more subsidiaries, including an incubator.
Rapt Therapeutics filed to raise up to $75 million in its IPO after postponing an earlier attempt to raise $86 million in August.
The termination of the clinical trial and molecule follows slower-than-expected progress for RG6174.
The series B round comes 16 months after Viela broke free from AstraZeneca with six drugs and $250 million in funding.
Viela's inebilizumab reduced attacks from the rare autoimmune disease neuromyelitis optica spectrum disorders by 73%.
Viela Bio came to be when AstraZeneca hived off a clutch of programs in inflammatory and autoimmune diseases.